Nrx Pharmaceuticals, INC. (NRXPW) — SEC Filings

Q: What are the key financial highlights for Nrx Pharmaceuticals, INC.?

Key financial highlights for Nrx Pharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Nrx Pharmaceuticals, INC.?

Key executives at Nrx Pharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Nrx Pharmaceuticals, INC. stock?

Risk factors for Nrx Pharmaceuticals, INC. (NRXPW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Nrx Pharmaceuticals, INC.?

Forward-looking statements and predictions from Nrx Pharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Nrx Pharmaceuticals, INC.. Recent 8-K filing on Dec 29, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Nrx Pharmaceuticals, INC. on SEC EDGAR

Overview

Nrx Pharmaceuticals, INC. (NRXPW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: NRX Pharmaceuticals, Inc. filed an 8-K on December 29, 2025, reporting an event on December 18, 2025. The filing indicates the company's incorporation in Delaware and its standard industrial classification as Pharmaceutical Preparations. It also lists its former name as Big Rock Partners Acquisition

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant filing sentiment for Nrx Pharmaceuticals, INC. is neutral.

Filing Type Overview

Nrx Pharmaceuticals, INC. (NRXPW) has filed 35 8-K, 1 8-K/A, 5 10-Q, 2 10-K/A, 2 10-K, 1 S-1, 1 DEF 14A, 3 DEFA14A with the SEC between Mar 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

NRX Pharmaceuticals Files 8-K — 8-K · Dec 29, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on December 29, 2025, reporting an event on December 18, 2025. The filing indicates the company's incorporation in Delawa
8-K Filing — 8-K · Nov 26, 2025
8-K/A Filing — 8-K/A · Nov 21, 2025
NRX Pharmaceuticals' Net Loss Widens Amidst R&D Shifts, Revenue Debut — 10-Q · Nov 14, 2025 Risk: high
NRX Pharmaceuticals, Inc. (NRXP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $28.98 million, up from $16.
NRX Pharmaceuticals Files 8-K — 8-K · Oct 23, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting events as of October 17, 2025. The filing includes information related to Regulation FD Di
NRX Pharmaceuticals Files 8-K — 8-K · Sep 26, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting on events that occurred on September 24, 2025. The filing primarily concerns financial s
NRX Pharmaceuticals Completes Asset Acquisition/Disposition — 8-K · Sep 12, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on September 12, 2025, reporting the completion of an acquisition or disposition of assets on September 8, 2025. The fili
NRX Pharmaceuticals Files 8-K with Financials — 8-K · Sep 8, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on September 8, 2025, reporting on events that occurred on September 2, 2025. The filing includes financial statements an
NRX Pharmaceuticals Q2 2025 Update: Revenue Flat, Assets Shift — 10-Q · Aug 18, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company reported $0.001 in revenue for the six months ended June 30, 2025, com
NRX Pharmaceuticals Files 8-K — 8-K · Aug 15, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on August 15, 2025, reporting on events that occurred on August 11, 2025. The filing primarily concerns financial stateme
NRX Pharmaceuticals Files 8-K Report — 8-K · Jun 9, 2025 Risk: low
On June 5, 2025, NRX Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Big Rock Partners
NRX Pharmaceuticals Files 8-K on Financials — 8-K · May 21, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on May 21, 2025, reporting on events as of May 15, 2025. The filing pertains to Results of Operations and Financial Condi
NRX Pharmaceuticals Q1 2025: Minimal Revenue, Significant Cash — 10-Q · May 15, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported $0.001 in revenue for the quarter. As of March 31, 2025, NRX P
NRX Pharmaceuticals Files 8-K — 8-K · May 13, 2025 Risk: low
On May 13, 2025, NRX Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. The company was fo
NRX Pharmaceuticals Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Big Rock
NRX Pharmaceuticals Files 8-K — 8-K · Apr 17, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on April 17, 2025, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acqu
NRX Pharmaceuticals Files 8-K on Financials — 8-K · Mar 21, 2025 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on March 21, 2025, reporting on results of operations, financial condition, and Regulation FD disclosures as of March 17,
NRX Pharmaceuticals Files 2024 10-K — 10-K · Mar 14, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed its 2024 10-K on March 14, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Big Rock Partners
NRX Pharmaceuticals Files 8-K — 8-K · Feb 3, 2025 Risk: medium
On January 28, 2025, NRX Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statemen
NRX Pharmaceuticals Files 8-K: Agreements & Equity Sales — 8-K · Jan 29, 2025 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on January 27, 2025, related to the creation of a direct financial obligation. The compan
NRX Pharmaceuticals Files 8-K on Officer/Director Changes — 8-K · Jan 22, 2025 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on January 22, 2025, reporting events as of January 15, 2025. The filing pertains to the departure of directors or certai
NRX Pharmaceuticals Appoints New CMO, Elects Directors — 8-K · Jan 14, 2025 Risk: medium
NRX Pharmaceuticals, Inc. announced on January 7, 2025, a significant change in its board of directors and executive compensation. The company appointed Dr. Jon
NRX Pharmaceuticals Files 8-K for Equity Sales — 8-K · Jan 10, 2025 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on January 6, 2025, related to unregistered sales of equity securities. The company, form
NRX Pharmaceuticals Appoints Dr. Javitt CEO, Chairman — 8-K · Nov 20, 2024 Risk: medium
NRX Pharmaceuticals, Inc. announced on November 18, 2024, the appointment of Dr. Jonathan Javitt as Chief Executive Officer and Chairman of the Board. Dr. Javit
NRX Pharmaceuticals Files 8-K on Financials — 8-K · Nov 15, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on November 15, 2024, reporting on its financial condition and results of operations as of November 14, 2024. The filing
NRX Pharmaceuticals Files S-1 Registration Statement — S-1 · Nov 14, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an S-1 registration statement on November 14, 2024, to register securities under the Securities Act of 1933. The company, former
NRX Pharmaceuticals Files 8-K — 8-K · Oct 31, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on October 31, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Ac
NRX Pharma Files 8-K on Financial Obligations & Equity Sales — 8-K · Oct 15, 2024 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on October 10, 2024, related to the creation of a direct financial obligation. The compan
NRX Pharmaceuticals Files 8-K on Corporate Governance Changes — 8-K · Oct 11, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on October 11, 2024, reporting on several key events that occurred on October 7, 2024. These include the departure of dir
NRX Pharmaceuticals Files 2024 Proxy Statement — DEF 14A · Sep 5, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed a DEF 14A on September 5, 2024, for its annual meeting on October 8, 2024. The company, formerly known as Big Rock Partners Acqu
NRX Pharmaceuticals Board Changes and Officer Compensation — 8-K · Aug 20, 2024 Risk: medium
NRX Pharmaceuticals, Inc. announced on August 14, 2024, a change in its board of directors. Specifically, Dr. Jonathan Rothbard resigned from the Board of Direc
NRX Pharmaceuticals Files 8-K on Financials — 8-K · Aug 15, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition as of August 14, 2024. The filing incl
NRX Pharmaceuticals Files 10-Q, Details Stock Changes — 10-Q · Aug 14, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported significant changes in its capital structure, including an in
NRX Pharmaceuticals Faces Delisting Concerns — 8-K · Aug 12, 2024 Risk: high
NRX Pharmaceuticals, Inc. filed an 8-K on August 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was forme
NRX Pharmaceuticals Terminates Material Agreement — 8-K · Jun 27, 2024 Risk: medium
NRX Pharmaceuticals, Inc. announced the termination of a material definitive agreement on June 21, 2024. The company also reported other events on the same date
NRX Pharmaceuticals Reports Director/Officer Changes & Financials — 8-K · Jun 20, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on June 20, 2024, reporting changes effective June 13, 2024. The filing pertains to the departure of directors or certain
NRX Pharmaceuticals Closes $10M Convertible Note Offering — 8-K · May 23, 2024 Risk: medium
On May 21, 2024, NRX Pharmaceuticals, Inc. filed an 8-K report detailing the completion of a private placement of convertible notes. The company issued $10.0 mi
NRX Pharmaceuticals Files 8-K — 8-K · May 16, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on May 16, 2024, reporting on events as of May 14, 2024. The filing includes information on results of operations, financ
NRX Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
NRX Pharmaceuticals, Inc. (NRXPW) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. NRX Pharmaceuticals, Inc. filed a 10-Q report for the period end
NRX Pharmaceuticals Files 8-K on Financial Obligations — 8-K · Apr 30, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on April 30, 2024, reporting on events that occurred on April 24, 2024. The filing indicates a triggering event related t
NRX Pharmaceuticals Files Amendment to 2023 Annual Report — 10-K/A · Apr 29, 2024 Risk: low
NRX Pharmaceuticals, Inc. (NRXPW) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. NRX Pharmaceuticals filed an amendment (10-K/A) to its
NRX Pharmaceuticals Enters Material Definitive Agreement — 8-K · Apr 19, 2024 Risk: medium
NRX Pharmaceuticals, Inc. entered into a material definitive agreement on April 17, 2024. The company, formerly known as Big Rock Partners Acquisition Corp., is
NRX Pharmaceuticals Files 8-K — 8-K · Apr 15, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on April 15, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acqu
NRX Pharmaceuticals Files 8-K on Financials — 8-K · Apr 2, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on April 2, 2024, reporting on its results of operations and financial condition as of April 1, 2024. The filing includes
NRX Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk:
NRX Pharmaceuticals, Inc. (NRXPW) filed a Annual Report (10-K) with the SEC on March 29, 2024. NRX Pharmaceuticals, Inc. filed its 2023 Form 10-K on March 29, 2
NRX Pharmaceuticals Files 8-K on Security Holder Rights — 8-K · Mar 28, 2024 Risk: medium
NRX Pharmaceuticals, Inc. filed an 8-K on March 28, 2024, to report material modifications to security holder rights and amendments to its articles of incorpora
NRX Pharmaceuticals Files 8-K — 8-K · Mar 21, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed an 8-K on March 21, 2024, reporting on the submission of matters to a vote of security holders, Regulation FD disclosures, and f
NRX Pharmaceuticals Files Proxy Statement — DEFA14A · Mar 20, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on March 20, 2024. This filing relates to the company's proxy materials, which are typica
NRX Pharma Files Proxy Statement for Share Distribution — DEFA14A · Mar 18, 2024 Risk: medium
NRX Pharmaceuticals, Inc. (NRXP) filed a DEFA14A, indicating it is a definitive proxy statement. The filing relates to the company's plan to distribute shares o
NRX Pharmaceuticals Files Proxy Statement — DEFA14A · Mar 13, 2024 Risk: low
NRX Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on March 13, 2024. This filing is related to the company's proxy materials, which are typ

Risk Profile

Risk Assessment: Of NRXPW's 47 recent filings, 2 were flagged as high-risk, 26 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Nrx Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 14, 2025):

Revenue: $0.24M
Net Income: -$28.98M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $7.18M
Operating Margin: N/A
Total Assets: $14.99M
Total Debt: $40.75M

Key Executives

Rebecca Cohen
Dr. Jonathan Roth
Mr. Jonathan Roth
Dr. Jonathan Javitt
Dr. Stephen R. Smith
Jonathan Javitt
Dr. Jonathan Rothbard

Industry Context

The biopharmaceutical industry, particularly in the central nervous system (CNS) disorder space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like NRX Pharmaceuticals operate in a competitive landscape where success hinges on clinical trial outcomes and FDA approvals. Trends include a growing focus on novel therapeutics for unmet medical needs and the increasing importance of financing activities to sustain operations during the lengthy development phases.

Top Tags

8-K (10) · filing (9) · financials (8) · corporate-action (6) · pharmaceuticals (5) · financial-reporting (5) · regulatory-filing (5) · corporate-governance (5) · corporate-event (4) · 10-Q (4)

Key Numbers

Net Loss: $28.98M — for the nine months ended September 30, 2025, increased from $16.05M in 2024
Cash and Cash Equivalents: $7.18M — as of September 30, 2025, up from $1.44M at December 31, 2024
Warrant Liabilities: $15.86M — as of September 30, 2025, increased from $5.64M at December 31, 2024
Convertible Note Payable and Accrued Interest, Current: $9.91M — as of September 30, 2025, increased from $1.25M at December 31, 2024
Net Patient Service Revenue: $0.24M — for the nine months ended September 30, 2025, first revenue generation
Research and Development Expenses: $3.22M — for the nine months ended September 30, 2025, decreased from $5.16M in 2024
Selling, General and Administrative Expenses: $8.49M — for the nine months ended September 30, 2025, decreased from $10.90M in 2024
Net Cash Provided by Financing Activities: $18.70M — for the nine months ended September 30, 2025
Common Stock Shares Outstanding: 27,682,530 — as of September 30, 2025, increased from 14,591,505 at December 31, 2024
Total Stockholders' Deficit: $25.76M — as of September 30, 2025, increased from $23.22M at December 31, 2024
SEC File Number: 001-38302 — Identifies the company's filing with the SEC
IRS Employer Identification No.: 82-2844431 — Tax identification number for the company
Revenue (6 months ended 06/30/2025): $0.001 — Indicates minimal sales activity.
Total Assets (06/30/2025): $19,473,588 — Represents the company's total resources.
Authorized Common Stock: 50,000,000 — Indicates the maximum number of shares the company can issue.

Related Companies

NRXP

Frequently Asked Questions

What are the latest SEC filings for Nrx Pharmaceuticals, INC. (NRXPW)?

Nrx Pharmaceuticals, INC. has 50 recent SEC filings from Mar 2024 to Dec 2025, including 35 8-K, 5 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NRXPW filings?

Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Nrx Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Nrx Pharmaceuticals, INC. (NRXPW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Nrx Pharmaceuticals, INC.?

Key financial highlights from Nrx Pharmaceuticals, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for NRXPW?

The investment thesis for NRXPW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Nrx Pharmaceuticals, INC.?

Key executives identified across Nrx Pharmaceuticals, INC.'s filings include Rebecca Cohen, Dr. Jonathan Roth, Mr. Jonathan Roth, Dr. Jonathan Javitt, Dr. Stephen R. Smith and 2 others.

What are the main risk factors for Nrx Pharmaceuticals, INC. stock?

Of NRXPW's 47 assessed filings, 2 were flagged high-risk, 26 medium-risk, and 19 low-risk.

What are recent predictions and forward guidance from Nrx Pharmaceuticals, INC.?

Forward guidance and predictions for Nrx Pharmaceuticals, INC. are extracted from SEC filings as they are enriched.